DK479083A - Materialer og metoder til herpes simplex-virus-vaccination - Google Patents

Materialer og metoder til herpes simplex-virus-vaccination Download PDF

Info

Publication number
DK479083A
DK479083A DK479083A DK479083A DK479083A DK 479083 A DK479083 A DK 479083A DK 479083 A DK479083 A DK 479083A DK 479083 A DK479083 A DK 479083A DK 479083 A DK479083 A DK 479083A
Authority
DK
Denmark
Prior art keywords
materials
methods
herpes simplex
simplex virus
virus vaccination
Prior art date
Application number
DK479083A
Other languages
English (en)
Other versions
DK172619B1 (da
DK479083D0 (da
Inventor
Gary H Cohen
Roselyn J Eisenberg
Original Assignee
University Patents Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26996451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK479083(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University Patents Inc filed Critical University Patents Inc
Publication of DK479083A publication Critical patent/DK479083A/da
Publication of DK479083D0 publication Critical patent/DK479083D0/da
Application granted granted Critical
Publication of DK172619B1 publication Critical patent/DK172619B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/22—Viral peptide or viral protein
    • Y10S930/224—Herpes related
DK198304790A 1982-02-18 1983-10-17 Fremgangsmåde til isolering af immunogene præparater af herpes simplex virus type 1 og type 2, fremgangsmåde til fremstill DK172619B1 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US35002182A 1982-02-18 1982-02-18
US35002182 1982-02-18
US46314183 1983-02-04
US06/463,141 US4762708A (en) 1982-02-18 1983-02-04 Materials and methods for herpes simplex virus vaccination
US8300182 1983-02-14
PCT/US1983/000182 WO1983002897A1 (en) 1982-02-18 1983-02-14 Materials and methods for herpes simplex virus vaccination

Publications (3)

Publication Number Publication Date
DK479083A true DK479083A (da) 1983-10-17
DK479083D0 DK479083D0 (da) 1983-10-17
DK172619B1 DK172619B1 (da) 1999-03-01

Family

ID=26996451

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198304790A DK172619B1 (da) 1982-02-18 1983-10-17 Fremgangsmåde til isolering af immunogene præparater af herpes simplex virus type 1 og type 2, fremgangsmåde til fremstill

Country Status (20)

Country Link
US (1) US4762708A (da)
EP (1) EP0101506B1 (da)
JP (3) JP2665332B2 (da)
KR (1) KR910006889B1 (da)
AR (1) AR231496A1 (da)
AT (1) ATE54827T1 (da)
AU (1) AU554710B2 (da)
CA (1) CA1236774A (da)
DE (1) DE3381761D1 (da)
DK (1) DK172619B1 (da)
ES (1) ES519875A0 (da)
FI (2) FI73885C (da)
GR (1) GR77900B (da)
HU (1) HU195734B (da)
IE (1) IE56479B1 (da)
IL (5) IL80896A (da)
NO (2) NO162366B (da)
NZ (1) NZ220771A (da)
PH (1) PH25689A (da)
WO (1) WO1983002897A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540669A (en) * 1980-09-11 1985-09-10 Merck & Co., Inc. Herpes simplex type I subunit vaccine
US5149660A (en) * 1982-02-18 1992-09-22 University Patents, Inc. Diagnostic reagents relating to herpes simplex virus
NZ209307A (en) * 1983-08-30 1990-07-26 Genentech Inc Diagnostic product: antigenic peptide produced by recombinant dna techniques
US7264817B1 (en) 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
JPS6051120A (ja) * 1983-08-31 1985-03-22 Chemo Sero Therapeut Res Inst 単純ヘルペスサブユニットワクチン
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5612041A (en) * 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
JPS6153226A (ja) * 1984-08-24 1986-03-17 Chemo Sero Therapeut Res Inst 単純ヘルペスサブユニツトワクチンの精製方法
ATE72123T1 (de) * 1985-04-19 1992-02-15 Wistar Inst Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort.
GB8605390D0 (en) * 1986-03-05 1986-04-09 Univ Birmingham Live herpes simplex vaccine
WO1990013652A1 (en) * 1989-05-12 1990-11-15 Triton Diagnostics, Inc. Herpes simplex virus type 2-glycoprotein g proteins and polypeptides
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5654174A (en) * 1995-07-07 1997-08-05 Competitive Technologies, Inc. Herpes simplex virus glycoprotein D variants
US20020090382A1 (en) * 2000-08-01 2002-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Antiviral compounds and methods
US20030219448A1 (en) * 2002-05-24 2003-11-27 Cedars-Sinai Medical Center Peptide epitope-based vaccine for treating herpes simplex virus infections and related diseases
EP1523582B1 (en) 2002-07-18 2008-11-12 University of Washington Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same
US8541002B2 (en) * 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
US8865185B2 (en) * 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
EP2059255A4 (en) * 2006-09-08 2011-08-31 Univ Pennsylvania VACCINES AGAINST HSV-1 AND HSV-2 AND METHODS OF USE
US20130028925A1 (en) * 2006-12-28 2013-01-31 Harvey Friedman Herpes simplex virus combined subunit vaccines and methods of use thereof
AU2007342345B9 (en) * 2006-12-28 2013-09-12 The Trustees Of The University Of Pennsylvania Herpes Simplex Virus combined subunit vaccines and methods of use thereof
US10478490B2 (en) * 2006-12-28 2019-11-19 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US8057804B2 (en) * 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
WO2011106607A2 (en) 2010-02-26 2011-09-01 Juvaris Biotherapeutics, Inc. Subunit vaccines for herpes viruses and methods of use
WO2012139106A2 (en) * 2011-04-08 2012-10-11 Duke University Herpes simplex virus
PL2850431T3 (pl) 2012-05-16 2018-09-28 Immune Design Corp. Szczepionki przeciwko HSV-2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4374127A (en) * 1977-09-19 1983-02-15 Merck & Co., Inc. Herpes sub unit vaccine
ES8105035A1 (es) * 1978-12-22 1981-05-16 Biogen Nv Un metodo para producir al menos un polipeptido que muestra antigenicidad de hbv

Also Published As

Publication number Publication date
EP0101506A4 (en) 1984-07-06
JPH0769924A (ja) 1995-03-14
US4762708A (en) 1988-08-09
JPH0797396A (ja) 1995-04-11
WO1983002897A1 (en) 1983-09-01
JP2567202B2 (ja) 1996-12-25
FI73885C (fi) 1987-12-10
FI833768A (fi) 1983-10-17
JP2669594B2 (ja) 1997-10-29
NO162366B (no) 1989-09-11
NO842962L (no) 1983-10-17
IL80896A0 (en) 1987-03-31
IL67930A (en) 1990-02-09
CA1236774A (en) 1988-05-17
JP2665332B2 (ja) 1997-10-22
FI73885B (fi) 1987-08-31
EP0101506A1 (en) 1984-02-29
DK172619B1 (da) 1999-03-01
NO833773L (no) 1983-10-17
KR840003420A (ko) 1984-09-08
NZ220771A (en) 1990-09-26
NO172745B (no) 1993-05-24
NO172745C (no) 1993-09-01
ATE54827T1 (de) 1990-08-15
ES8406199A1 (es) 1984-08-01
FI864102A (fi) 1986-10-10
PH25689A (en) 1991-09-04
FI83880B (fi) 1991-05-31
AU1339683A (en) 1983-09-08
FI864102A0 (fi) 1986-10-10
EP0101506B1 (en) 1990-07-25
HU195734B (en) 1988-07-28
JPS59500216A (ja) 1984-02-16
KR910006889B1 (ko) 1991-09-10
IL80896A (en) 1990-02-09
IL80895A0 (en) 1987-03-31
IL80895A (en) 1990-02-09
DE3381761D1 (de) 1990-08-30
FI833768A0 (fi) 1983-10-17
ES519875A0 (es) 1984-08-01
AU554710B2 (en) 1986-08-28
IL67930A0 (en) 1983-06-15
IE56479B1 (en) 1991-08-14
FI83880C (fi) 1991-09-10
DK479083D0 (da) 1983-10-17
GR77900B (da) 1984-09-25
AR231496A1 (es) 1984-12-28
IE830332L (en) 1983-08-18

Similar Documents

Publication Publication Date Title
DK479083D0 (da) Materialer og metoder til herpes simplex-virus-vaccination
DK401583A (da) Parenkymal celle-cellulose og beslaegtede materialer
DK276683A (da) Carbapenemer og fremgangsmaade til fremstilling deraf
NO822671L (no) Farmasoeytisk virksomme forbindelser og fremgangsmaate for deres fremstilling.
DK557383D0 (da) Monoclone antistoffer og deres anvendelse
DK157683A (da) N-phosphonomethylglycinderivater og fremgangsmaade til fremstilling og anvendelse deraf
DK590383A (da) Pyrimidonderivater og fremgangsmaade til fremstilling heraf
DK333183D0 (da) Fremgangsmade til fremstilling af herpes simplex virusglycoproteiner
DK290583D0 (da) Benzoylpiperazinestre og fremgangsmade til deres fremstilling
DK384183A (da) Mordenit og fremgangsmaade til fremstilling deraf
DK158844C (da) Saltsyrepraeparater og anvendelse heraf
DK251281A (da) N6-adenosiner og fremgangsmaader til deres fremstilling
DK165336C (da) Koncentrerede stofbloedgoerende midler og fremgangsmaader til deres fremstilling
DK271281A (da) Haardfeldt og fremgangsmaade til fremstilling deraf
DK343183D0 (da) Ketoquinoliner og fremgangsmade til fremstilling deraf
DK482583D0 (da) Dna-sekvens, dna-strukturer og fremgangsmade til fremstilling af penicillin-acylase under anvendelse deraf
DK20781A (da) Thioler og fremgangsmaader til deres fremstilling
DK81192D0 (da) Substituerede ethandiimidamider og fremgangsmaade til fremstilling deraf
DK522883A (da) 2-heterocyclylthio-alkyl-2-penem-forbindelser samt deres fremstilling og anvendelse
ZA831097B (en) Materials and methods for herpes simplex virus vaccination
DK435283A (da) Diastereomerer og fremgangsmaade til fremstilling deraf
IT8147772A0 (it) Procedimento per preparare 2-ammino 5-nitro-benzofenone e suoi 2-aloge no-derivati
DK372885A (da) Vaccine og fremgangsmaade til fremstilling heraf
DE3588244T2 (de) Rekombinanter Herpes Simplex gB-gD-Impfstoff
DK82282A (da) Formstof og fremgangsmaade til fremstilling deraf

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed